Hsbc Holdings PLC Replimune Group, Inc. Transaction History

Hsbc Holdings PLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$5.01 - $9.46 $85,530 - $161,501	17,072 Added 139.11%	29,344 $264,000
Q1 2024 May 15, 2024	SELL	$6.87 - $9.31 $77,356 - $104,830	-11,260 Reduced 47.85%	12,272 $100,000
Q4 2023 Feb 12, 2024	BUY	$6.75 - $16.18 $25,744 - $61,710	3,814 Added 19.34%	23,532 $198,000
Q3 2023 Nov 13, 2023	BUY	$15.96 - $22.18 $98,058 - $136,273	6,144 Added 45.26%	19,718 $337,000
Q2 2023 Aug 11, 2023	BUY	$15.65 - $24.1 $212,433 - $327,133	13,574 New	13,574 $315,000

149

68M

52.3K

80.3K

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $693M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Hsbc Holdings PLC with notifications on news.